HumaScan downgrades payment to Scantek:
This article was originally published in Clinica
Following the FDA's warning letter to HumaScan last month over its BreastAlert differential temperature sensor for use as an adjunct in breast cancer detection, the company has announced changes to its US licensing deal with Scantek Medical. Scantek licenses the technology to HumaScan. The new arrangements include elimination of $450,000 in royalties due in the first two years of production, a further cancellation of $200,000 in connection with acquiring production machinery and a reduction of $375,000 in cash licence fees.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.